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Summary
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic
syndrome characterized biochemically by hypophosphatemia,
excessive urinary phosphate excretion, low 1,25-dihydroxyvit-
amin D levels, and clinically by osteomalacia, pseudofrac-
tures, bone pain, fatigue, and muscle weakness. TIO can oc-
cur in patients with a variety of benign mesenchimal tumors
(hemangiopericitomas, fibromas, angiosarcomas, etc.) and
the disease is invariably curable with the removal of the tu-
mor, indicating that it has humoral basis. Phosphate wasting
and the defect in vitamin D synthesis are caused by a humoral
factor produced by tumors, initially termed phosphatonin, and
recently identified as fibroblast growth factor-23 (FGF-23) al-
though other substances as secreted frizzled-related protein 4
(SFRP4) and matrix extracellular phospho-glycoprotein
(MEPE) can be involved in pathophysiology of osteomalacia.
In contrast with more common forms of osteomalacia, pa-
tients with TIO have normal serum calcium, normal serum 25-
hydroxy-vitamin D and normal intact serum parathyroid hor-
mone. On the other hand TIO is biochemically indistinguish-
able from several inherited forms of hypophosphatemic rick-
ets as X-linked hypophosphatemia (XLH) and autosomical
dominant hypophosphatemic rickets (ADHR). The definitive
diagnosis of TIO is established by identification of the
causative tumor and remission of the syndrome after com-
plete tumor resection. Recently a few cases in which 111In-pen-
tetreotide scintigraphy visualized the tumor have been report-
ed and also positron emission tomography using F-18-fluoro-
deoxyglucose showed encouraging results. When the sus-
pected tumour cannot be located, periodical follow-up with
conventional imaging is indicated with special attention di-
rected to craniofacial locations and extremities because they
are the more common localization for tumour. In conclusion in
patients with TIO resection of a tumour is the treatment of
choice; if the tumour cannot be found or if the tumour is unre-
sectable for its location, chronic administration of phosphate
and calcitriol is indicated.
KEY WORDS: oncogenic osteomalacia, hypophosphoremia, fractures, oc-
treotide scintigraphy.
Introduction
Osteomalacia is a metabolic bone disorder characterized by
reduced mineralization and increase in osteoid thickness.
This disorder typically occurs in adults, due to different condi-
tions impairing matrix mineralization. Its major symptoms are
diffuse bone pain, muscle weakness and bone fractures with
minimal trauma. When occurs in children, it is associated with
a failure or delay in the mineralization of endochondral new
bone formation at the growth plates, causing gait distur-
bances, growth retardation, and skeletal deformities, and it is
called rickets. 
Histologically patients with osteomalacia present an abun-
dance of unmineralized matrix, sometimes to the extent that
whole trabeculae appeared to be composed of only osteoid
(Fig. 1). This will be depicted by quantitative histomorphome-
try as increases in osteoid volume, surface and thickness.
However, hyperosteoidoisis could be observed in other bone
diseases with a high turnover as hyperparathyroid states. The
osteomalacic nature of the hyperosteoidosis is being demon-
strated by defective mineralization, irregularity of mineraliza-
tion fronts, high number of osteoid lamellae, broad single
tetracycline fluorescent labels or no label at all, in contrast to
the normal double tetracycline fluorescent labels. These quali-
tative observations have to be supported by the unequivocal
changes in quantitative histomorphometry: decreases in a
double and single tetracycline labeled surface and in mineral
apposition rate as well as prolongation of mineralization lag
Oncogenic osteomalacia
Case report
Figure 1 - Osteomalacia. Excessive accumulation of osteoid and in-
creased width of osteoid seams. Undecalcified section of human iliac
bone (Von Kossa stain).
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time (1). 
Many cases of osteomalacia are related to vitamin D deficiency
(Tab. I). This condition, also named nutritional osteomalacia, can
be due to either estrinsic or intrinsic vitamin D deficiency. The
former is mainly related to low dietary intake or reduced sunlight
exposure, while intrinsic vitamin D deficiency is caused by an im-
paired intestinal absorption of vitamin D. Osteomalacia may also
occur due to impaired vitamin D metabolism. In rare circum-
stances, rickets may be due to hereditary disorders of vitamin D
metabolism (1-alfa-hydroxylase deficiency, causing type I vita-
min D dependent rickets) or vitamin D resistance due to im-
paired vitamin D receptors (causing type II vitamin D dependent
rickets). Finally, different conditions, such as phosphate deple-
tion, renal tubular acidosis, or treatment with fluorides and
etidronate, may cause vitamin D independent syndromes lead-
ing to osteomalacia.
Oncogenic osteomalacia or tumor-induced osteomalacia (TIO)
is an acquired disorder of isolated renal phosphate wasting
that is associated with tumors, often arising from a mesenchy-
mal tissue. It is a rare disorder with at least 120 cases reported
in the literature (2). The first case was described by McCance,
in 1947 (3), even thought the causal relationship between ma-
lignancy and osteomalacia was not recognized until 1959 (4).  
Pathophysiology
TIO is characterized by hypophosphatemia due to inhibition of
renal phosphorus reabsorption associated with a vitamin D
synthetic defect that blocks the compensatory rise in calcitriol
stimulated by the hypophosphatemia. Phosphate wasting and
the defect in vitamin D synthesis are caused by a humoral fac-
tor produced by mesenchymal tumors, termed phosphatonin.
Recently this substance has been identified as a 32-kD peptide
belonging to the Fibroblast Growth Factor family, FGF-23.
Other causes of selective renal wasting of phosphate are: 1) X-
linked hypophosphataemia (XLH); 2) autosomal dominant hy-
pophosphataemic rickets (ADHR); 3) hereditary hypophos-
phataemic rickets with hypercalciuria (HHRH).
TIO is usually characterized by generalized pain and muscle
weakness. Otherwise, TIO mimics the clinical phenotype of XLH
or ADHR. In patients with TIO, a family history of hypophos-
phatemia and bone disorders is absent and onset and severity of
symptoms are more acute than in the other hypophosphatemic
syndromes. XLH and ADHR typically present in childhood, al-
though ADHR can exhibit a variable and delayed age of onset.
On the other hand patients with TIO exhibit symptoms as weak-
ness, pain, and fractures that are more severe, with rapid pro-
gression to disability. However, also patients with adult-onset
ADHR may present severe bone pain and weakness. Stress
fractures are a prominent feature of osteomalacic states while
lower-extremity deformity and short stature are characteristic of
XLH and ADHR. HHRH replicates many features of the pheno-
type of XLH and ADHR but it is distinguished by an appropriate
increase of calcitriol and hypercalciuria (5, 6).
Shimada et al. (7) first identified FGF-23 as the humoral factor
produced by tumors and causing oncogenic osteomalacia.
When injected into mice FGF-23 produced mild phosphaturia
and hypophosphatemia. Moreover FGF-23 is high expressed in
mesenchymal tumors causing tumor-induced osteomalacia and
it is barely detectable in normal tissues such as liver, thymus,
heart, lymph nodes, brain (7, 8). FGF-23 exerts its activity at the
proximal renal tubule by the inhibition of tubular reabsorption of
phosphate and the downregulation of 25-hydroxy-vitaminD-1-hy-
droxylase, resulting in hypophosphatemia and osteomalacia (9). 
FGF-23 is also central in the pathogenesis of ADHR. Missense
mutations in 1 of 2 arginine residues at positions 176 or 179
have been identified in affected members of ADHR families.
These mutated arginine residues prevent the degradation of
FGF-23, resulting in prolonged and/or enhanced FGF-23 ac-
tion (10-14).
Additional evidence suggests that FGF-23 may also be the key
in the pathogenesis of XLH caused by mutations in the PHEX
gene (phosphate-regulating gene with homologies to endopepti-
dase on X chromosome), which encodes an endopeptidase.
Speculation about how loss of endopeptidase activity results in
phosphate wasting has led to the hypothesis that FGF-23 is a
substrate for PHEX and that failure to cleave FGF-23 prolongs
or enhances its activity. Although there is disagreement in the lit-
erature, PHEX is thought to, either directly (10, 15) or indirectly
(16, 17), regulate FGF-23. Thus, FGF-23 plays a central role in
the disorders of renal phosphate wasting. In TIO, tumors pro-
duce FGF-23 which exerts its activity at the proximal renal
tubule; in ADHR, FGF-23 bears mutations that enhance its bio-
Table I - Etiopathogenetic classification of osteomalacia.
Vitamin D deficiency
Estrinsic deficiency
Reduced sunlight exposure
Low dietary intake
Intrinsic deficiency
Impaired intestinal absorption
Gastrectomy
Celiac disease
Intestinal by-pass
Hepato-biliary disease
Chronic pancreatic deficiency
Impaired vitamin D metabolism
Deficiency of 25-OHD
Anticonvulsivant drugs
Hepatic chronic disease
Deficiency of 1,25-(OH)2D
Renal chronic insufficiency
Type I vitamin D dependent ipophospatemic rickets
Phosphate depletion
Low dietary intake
Drugs
Renal tubular acidosis
Selective renal wasting of phosphate
X-linked hypophosphataemia (XLH)
Autosomal dominant hypophosphataemic rickets (ADHR)
Hereditary hypophosphataemic rickets with hypercalciuria (HHRH)
Tumour-induced ostemalacia (TIO)
Vitamin D metabolism deficiency and normal phosphate
Mineralization inhibitor
Drugs
Acidosis
Deficiency of matrix mineralization
Fibrogenesis imperfecta ossium
Alkaline phosphatase disorders
Ipophosphatasia
Clinical Cases in Mineral and Bone Metabolism 2006; 3(1): 76-83 77
Oncogenic osteomalacia
ONCOGENIC_Martini  14/06/2006  10.27  Pagina 77
78 Clinical Cases in Mineral and Bone Metabolism 2006; 3(1): 76-83
G. Martini et al.
logical activity and render it resistant to proteolytic cleavage; in
XLH, mutated PHEX directly or indirectly leads to the accumula-
tion of FGF-23 in the circulation and exerts its phosphaturic ac-
tivity at the renal proximal tubule (Fig. 2). In some patients with
polyostotic fibrous dysplasia who exhibit renal phosphate wast-
ing, serum FGF-23 can be elevated, correlating with the severity
of skeletal involvement (18). However, FGF-23 is not the only
factor secreted by tumors that affects renal phosphate handling
and bone mineralization (19-22). Other compelling phosphatonin
candidates have been identified as secreted frizzled-related pro-
tein 4 (SFRP4) and matrix extracellular phospho-glycoprotein
(MEPE). Genetic studies of tumors inducing osteomalacia
showed a high level of expression of the RNA for SFRP4 (23)
and an evaluation of the biological effects of SFRP4 on opossum
kidney epithelial cells evidenced a reduction in phosphate reab-
sorption. Furthermore, infusion of SFRP4 to rats diminished
phosphate reabsorption without increasing the urinary AMPc lev-
els; this effect persisted in parathyroidectomized rats, indicating
that it was independent from PTH (24). The MEPE is a recently
identified gene with a high level of transcription in tumor induced
osteomalacia (25). It encodes an extracellular matrix protein, al-
so called MEPE. In mice, MEPE expression occurs chiefly in the
osteoblasts and is more marked during bone mineralization
phases. The MEPE expression was reduced by 1,25-OH-D3 in
HYP mice, a model of XLH characterized by a high level of
MEPE expression (26) and decreased MEPE hydrolysis related
to a PHEX gene mutation responsible for increased MEPE activ-
ity has been suggested (27). In cultures of human proximal
tubule epithelium, MEPE inhibited phosphate reabsorption. In
animals, intraperitoneal MEPE injection induced hypophos-
phatemia and hyperphosphaturia in a dose dependent manner.
Finally, an in vitro study showed dose dependent inhibition by
MEPE of murine osteoblastic mineralization in the presence of
BMP2 (22). However data on these new forms of phosphatonin
come from a limited number of studies and require confirmation. 
The tumors associated with TIO are of mesenchymal origin in
the large majority of patients (Tab. II). The occurrence of osteo-
malacia in patients with widespread fibrous dysplasia of bone
(28, 29), neurofibromatosis (30, 31) and linear nevus seba-
ceous syndrome (33) could also be tumor induced. However,
in one case of fibrous dysplasia (29) and linear nevus seba-
ceous syndrome (32) removal of the abnormal bone or skin le-
sions respectively resulted in biochemical and radiographic im-
provement. Oncogenic osteomalacia has also been associated
with osteosarcomas (33-35), angiosarcomas (36), chondrosar-
comas (37), and malignant neurinoma (38) as well as nonmes-
enchymal carcinomas of the prostate (39, 40) and lung (41),
chronic lymphocytic leukemia, and multiple myeloma (42).
Figure 2 - Hypotetical model of interaction between FGF-23 and PHEX.
Table II - Tumors frequently associated to osteomalacia.
Tumor type
> 10%
Hemangiopericytoma
5-10%
Mesenchymal tumor
Non-ossifying fibroma
Prostatic carcinoma
1-5%
Angiolipoma
Epidermal naevi
Malignant chondroblastoma
Giant cell chondroma
Giant cell granuloma
Giant cell tumor
Hemangioma
Hemangioendothelioma
Cavernous hemangioma
Ossifying mesenchymal tumor
Ossifying fibroma
Fibroangioma
Osteoblastoma
Benign osteoblastoma
Polyostotic fibrous dysplasia
Primary bone tumor
Sebaceous naevi
Sclerosing hemangioma
Synovial tumor
< 1%
Benign connective tissue tumor
Brown tumor
Degenerated osteoid
Diffuse giant cell tumor
Extraskeletal chondroma
Mesenchymal chondrosarcoma
Atypical chondroma
Giant cell fibrous malignat histiocytoma
Hemangiofibroma
Mesenchymal spindle cell tumor
Mesenchymoma
Mixed mesenchymal tumor
Vascular mesenchymoma
Myelomatosis
Neurinoma
Neuroma
Malignant neuroma
Oat cell carcinoma
Odontogenic fibroma
Fibrosarcoma
Low grade fibrosarcoma
Fibrous xanthoma
Osteochondroblastoma
Osteosarcoma
Paraganglioma
Sarcoma
Small cell carcinoma
Transitional cell carcinoma
Vascular tumor
1-alfa-hydroxylase
1-alfa-hydroxylase
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There are also reported cases of benign tumors becoming ma-
lignant over time.
The mesenchymal tumors associated with this kind of osteoma-
lacia have been variably described as sclerosing angioma, be-
nign angiofibroma, hemangiopericytoma, chondrosarcoma,
primitive mesenchymal tumor, soft-parts chondroma-like tumor,
and giant-cell tumor of bone. Weidner and Cruz (31) estab-
lished that the polymorphous mesenchymal tumors can be sub-
divided histologically into four distinct morphologic patterns: (a)
primitive-appearing, mixed connective tissue tumors; (b) os-
teoblastoma-like tumors; (c) non-ossifying fibroma-like tumors;
and (d) ossifying fibroma-like tumors. The most common of
these, the mixed connective tissue variant, occurs in soft tissue,
behaves in a benign fashion, and is characterized by variable
numbers of primitive appearing stromal cells growing in poorly
defined sheets and punctuated by clusters of osteoclast-like gi-
ant cells. Vascularity also is prominent, but in less-vascular ar-
eas, poorly developed cartilage or foci of osteoid or bone are
commonly present. The cartilage-like areas sometimes exhibit
considerable dystrophic calcification. The tumors are usually
small, slow-growing, difficult to locate, and present in obscure
areas. In this regard, many of the reported lesions have been
located in a relatively inaccessible area within bone, such as
within the femur or tibia, the nasopharynx, mandible, or a sinus.
Alternatively, small lesions have been found in the popliteal re-
gion, the groin, the suprapatellar area, and in the brain. FGF-23
is abundantly expressed in these tumors (10, 43).
Diagnostic evaluation
Clinical and biochemical characteristic
Oncogenic osteomalacia affects both sexes around the age of
40 years. It may affect children and adolescents in 20% of cas-
es. In most patients, clinical signs appear from several months
to many years before the discovery of the tumor. In some cas-
es, the presence of a neoplastic mass was noted long before
the onset of skeletal disease. 
The clinical symptoms of TIO are non specific and often lead to
an erroneous diagnosis. Bone pain has been reported in the
majority of patients and it may be associated with tenderness,
weakness and muscle pain (44-46). Pain in osteomalacia is
dull and poorly localized but clearly felt in the bones rather than
in the joints (1, 47). It is often persistent, made worse by
weight-bearing and contraction of locally attached muscles.
The pain is usually symmetrical, beginning in the low back, lat-
er spreading to the pelvis and hips, upper thighs, upper back,
and ribs. Lateral compression of the ribs and posterior com-
pression of the sternum are useful maneuvers to elicit pain.
Muscles of the proximal limb girdles, especially the lower, are
often weak, the severity varying from a slight abnormality to se-
vere disability verging on complete paralysis. Specific symp-
toms include difficult in rising from a chair or walking up or
down stairs without using the arms (1). Abnormal gait is the
most frequent clinical manifestation of osteomalacia, and it can
be the result of either pain or weakness, but usually both con-
tribute. The combination of trunk oscillation, short steps, and
wide track contributes the classic penguin or duck-like wad-
dling gait of advanced osteomalacia (48). Children with TIO al-
so display rachitic features including gait disturbances, growth
retardation, and skeletal deformities. 
The constant biochemical markers of TIO are severe hy-
pophosphatemia, ranging from 0.7 to 2.4 mg/dl. Hyperphos-
phaturia, increased serum alkaline phosphatase and low plas-
ma concentration of 1.25-dihydroxy-vitamin D are also frequent
(1). 
The serum calcium is usually normal but mild hypocalcemia
has been described. The serum PTH levels are usually within
normal limits, but have been found low or high in some cases
(44-46). Circulating levels of 25-hydroxy-vitamin D are normal
and there are not glycosuria and aminoaciduria (49). Hy-
pophosphatemic osteomalacia can be a rare but important
complication of multiple myeloma. In these cases, the patho-
physiology of the phosphate renal wasting is notably different
from oncogenic osteomalacia and is due to light-chain
nephropathy, resulting in proximal tubular dysfunction (50). 
In cases in whom inherited hypophosphatemic rickets must be
excluded, genetic tests for mutations of the PHEX gene (defec-
tive in XLH) and the FGF-23 gene (defective in ADHR) are
useful (51).
Recently a serum assays has been developed to determine if
circulating concentrations of FGF-23 were elevated in TIO pa-
tients. The first reported assay was an ‘intact’ FGF-23 ELISA
assay that used confirmation-specific monoclonal antibodies to
N- and to C-terminal portions of FGF-23 (52). By this method,
FGF-23 can be detected in normal individuals with a mean cir-
culating concentration of approximately 30 pg/ml without corre-
lation with age. The single TIO patient tested in this study had a
serum FGF-23 concentration approximately nine-fold above
controls before tumor resection. After tumor removal, circulating
FGF-23 concentrations decreased within 30 min, and serum
phosphorus improved within 6 h (52). The rapid fall of FGF-23
post-tumor resection and rapid rise in serum phosphorus con-
centrations was also confirmed by findings in subsequent TIO
cases (53-55). In a study with a large number of controls and
TIO patients, the C-terminal ELISA was used to assess the role
of FGF-23 in TIO (53). This study confirmed that FGF-23 can be
detected in the circulation of normal individuals, and demon-
strated that the mean FGF-23 was greater than 10-fold in the
TIO patients tested compared to controls. Interestingly, in a
manner similar to XLH patients, some TIO patients had serum
concentrations within the normal range (56).
Imaging
In osteomalacia conventional radiography can reveal a marked
decrease of bone density and multiple pseudo-fractures. Tech-
netium-99m bone scintigraphy demonstrates diffuse skeletal
uptake, referred to as a “superscan”, and focal uptake at sites
of fractures. Reduced bone density can be determinated also
by dual-energy X-ray absorptiometry (DEXA) but it is impossi-
ble to distinguish the underlying aetiology of the osteomalacia
with these techniques. 
Repeated attempts to identify the tumour by physical examina-
tion and conventional imaging studies are frequently unreward-
ing, so that surgical treatment cannot be performed. Recently,
a few cases in which 111In-pentetreotide scintigraphy visualized
the tumor were reported (57-60). Indeed, “in vitro” studies
showed that many mesenchymal tumors express somatostatin
receptors (61) and also lesions smaller than 1 cm may be visi-
ble if receptor density is high, producing strong radioisotope
uptake with a sharp contrast between the tumour and the back-
ground noise (Fig. 3). However, phosphaturic syndromes are
not always related to oncogenic osteomalacia, so that a nega-
tive somatostatin receptor scan is not necessarily a false-nega-
tive result. Because identification and surgical removal of the
tumor is extremely beneficial to the patient and in view of the
high failure rate of conventional imaging techniques to identify
these small tumours, it seems reasonable to recommend 111In-
pentetreotide scintigraphy as the initial imaging study in the as-
sessment of patients with suspected oncogenic osteomalacia
(60). However it is important to underline that not all oncogenic
osteomalacia tumours express somatostatin receptors, or can
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be detected with octreotide scanning. 
Positron emission tomography (PET) using F-18-fluoro-deoxyglu-
cose (FDG) is the most important nuclear medicine procedure
applied to oncology for diagnosis and staging (62). The clinical
impact of 18F-FDG PET has been reported for many different tu-
mor types. In an extensive review of the 18F-FDG PET literature,
the overall sensitivity and specificity was estimated to be 84%
and 86%, respectively, and the results from 18F-FDG PET
changed the management in approximately one third of the pa-
tients (63). Tumor imaging with 18F-FDG is based on the fact that
malignant tumors with high metabolic rates take up greater
amounts of glucose and 18F-FDG than surrounding tissues. Not
all malignant tissues have avidity for 18F-FDG. Some types of
cancer tissues with low malignant potential, such as carcinoid tu-
mor, bronchoalveolar cancer, and mucinous adenocarcinoma,
use 18F-FDG at the same rate as normal surrounding tissues,
leading to failure in identifying these kind of cancers (64-67). In a
case-report 18F-FDG PET was used to confirm the diagnosis of
oncogenic osteomalacia: a search was conducted for a mes-
enchymal tumor by total body CT, MRI, and 111-indium octreotide
scintigraphy with negative results. PET images demonstrated an
isolated focus in the mouth region. Selective MRI confirmed the
presence of a solid mass between the 37th and 38th tooth (68).
When we use CT or MRI particular attention must make to cran-
iofacial regions and extremities because these are the most fre-
quent localizations of these kind of tumours (Fig. 4).
Treatment
In patients with TIO resection of the tumour is the treatment of
choice (Fig. 5) (69). If the tumour cannot be found or if the tu-
80 Clinical Cases in Mineral and Bone Metabolism 2006; 3(1): 76-83
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Figure 3 - Tumour of the lung causing TIO localized by 111In-octreotide scintigraphy.
Figure 4 - Head CT scan showing an ossyfyng fibroma-like tumour of
frontal sinus.
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mour is unresectable because of its location, chronic adminis-
tration of phosphate and calcitriol is indicated. Some patients
can be made asymptomatic and maintain a good quality of life
on these two medications. Regular monitoring of biochemistry
(every 3 months) ensures compliance and safety. It is prefer-
able to initiate oral treatment with phosphate, equivalent to 3
g/day elementary phosphorus, in divided doses, and adjust the
dose according to gastrointestinal tolerance and biochemical
response. If oral phosphate is not tolerated because of diar-
rhea, long-term intravenous infusion is an option. Because the
solution is hyperosmolar it must be administered by central
catheter and carries the risk of catheter-related infection. The
healing process can be expedited by using larger doses of cal-
citriol initially up to 5 mcg/day to achieve supraphysiological
concentrations of the hormone. As the serum alkaline phos-
phatase falls to normal it is prudent to reduce the dose of cal-
citriol to 1-2 mcg/day. If the osteomalacia is accompanied by a
normal alkaline phosphatase it is better to monitor the re-
sponse to 1 mcg doses of calcitriol initially, only increasing the
dose if there is no clinical improvement. Long-term monitoring
is necessary to ensure that there is no evidence of developing
hyperparathyroidism. Indeed tertiary hyperparathyroidism re-
quiring parathyroidectomy may develop if too much phosphate
or too little calcitriol is used; hence the need for regular follow-
up, including PTH measurements (70). In those cases deemed
to be idiopathic, careful reexamination for small tumours
should be undertaken; but where a patient is easily managed
medically, exhaustive reinvestigations looking for small benign
lesions are not necessary.
There is also some experience with the administration of oc-
treotide (57). In a case, treatment with subcutaneous oc-
treotide, 50 to 100 µg 3 times a day, resulted in correction of
hypophosphatemia, improvement in phosphaturia, and reduc-
tion of alkaline phosphatase (57). However, in 2 other patients,
despite 8 weeks of treatment with subcutaneous octreotide, up
to 200 µg 3 times daily, serum levels of phosphorus and cal-
citriol failed to increase, and tubular reabsorption of phosphate
remained depressed (60). Given the limited experience with
octreotide treatment in TIO, this therapy should be reserved for
the most severe cases that are refractory to current medical
therapy (51).
Conclusions
TIO is a rare disorder that presents with muscle weakness,
bone pain, and osteomalacia. Because the symptoms are often
non-specific, the measurement of serum phosphorus can be
very useful in patients with bone pain of unclear origin, muscle
weakness and fractures. Tumor-induced osteomalacia is usu-
ally caused by benign mesenchimal tumours and cure can be
achieved by complete resection of these tumours. From this
point of view, the location of the tumour is of paramount impor-
tance.
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